OBJECTIVE: In breast cancer, 2 molecular targets are well established (ER/PR and HER2), and therapies directed to these proteins have demonstrated to be clinically useful. METHODS: Despite the presence of the ER and PR, only half of the patients will respond to endocrine therapy, and less than 35% of patients with ErbB2-overexpressing metastatic breast cancer will respond to trastuzumab as a single agent. RESULTS: To improve survival of metastatic breast cancer patients with ER/PR positive and HER2 positive is critical to elucidate the mechanism of resistance or sensitivity of these tumors for a better selection depending on biologic molecular alterations. CONCLUSIONS: Recently, several studies addressing this issue have been reported. Here, we will focus on a comprehensive review of the currently available data.
OBJECTIVE: In breast cancer, 2 molecular targets are well established (ER/PR and HER2), and therapies directed to these proteins have demonstrated to be clinically useful. METHODS: Despite the presence of the ER and PR, only half of the patients will respond to endocrine therapy, and less than 35% of patients with ErbB2-overexpressing metastatic breast cancer will respond to trastuzumab as a single agent. RESULTS: To improve survival of metastatic breast cancerpatients with ER/PR positive and HER2 positive is critical to elucidate the mechanism of resistance or sensitivity of these tumors for a better selection depending on biologic molecular alterations. CONCLUSIONS: Recently, several studies addressing this issue have been reported. Here, we will focus on a comprehensive review of the currently available data.
Authors: Steven D Quinn; Shwetha Srinivasan; Jesse B Gordon; Wei He; Kermit L Carraway; Matthew A Coleman; Gabriela S Schlau-Cohen Journal: Biochemistry Date: 2018-04-06 Impact factor: 3.162
Authors: Tiffany M Scharadin; Wei He; Yianni Yiannakou; Alexey A Tomilov; Matthew Saldana; Gino A Cortopassi; Kermit L Carraway; Matthew A Coleman; Paul T Henderson Journal: PLoS One Date: 2017-06-06 Impact factor: 3.240
Authors: Javier Pérez-Pena; Janos Tibor Fekete; Raquel Páez; Mariona Baliu-Piqué; José Ángel García-Saenz; Vanesa García-Barberán; Aránzazu Manzano; Pedro Pérez-Segura; Azucena Esparis-Ogando; Atanasio Pandiella; Balázs Gyorffy; Alberto Ocana Journal: Front Immunol Date: 2019-12-18 Impact factor: 7.561